<DOC>
	<DOC>NCT00075959</DOC>
	<brief_summary>This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.</brief_summary>
	<brief_title>Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Disufenton sodium</mesh_term>
	<criteria>Males and females Intracerebral Hemorrhage as the cause of stroke symptoms Onset of symptoms within 6 hours Full functional independence prior to the present stroke Unconsciousness Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition. Severe illness with life expectancy less than 6 months. Known severe kidney disorder. Current known alcohol or illicit drug abuse or dependence. Pregnant or breastfeeding. Treatment with acetazolamide and methotrexate is not permitted during the infusion Participation in a previous clinical study within 7 days. Meets all other exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Stroke</keyword>
	<keyword>cerebral vascular accident</keyword>
	<keyword>CVA</keyword>
	<keyword>Hemorrhage</keyword>
	<keyword>Intracerebral Hemorrhage (ICH)</keyword>
	<keyword>Brain Attack</keyword>
	<keyword>Cataplexy</keyword>
</DOC>